Context Therapeutics Inc (NASDAQ: CNTX) on Monday, soared 8.65% from the previous trading day, before settling in for the closing price of $1.04. Within the past 52 weeks, CNTX’s price has moved between $0.49 and $1.55.
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 4.72%. The company achieved an average annual earnings per share of 24.18%. With a float of $61.00 million, this company’s outstanding shares have now reached $91.88 million.
Context Therapeutics Inc (CNTX) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Context Therapeutics Inc is 33.61%, while institutional ownership is 43.09%. The most recent insider transaction that took place on Jun 09 ’25, was worth 70,080. In this transaction Chief Executive Officer of this company bought 100,000 shares at a rate of $0.70, taking the stock ownership to the 920,190 shares. Before that another transaction happened on Jun 06 ’25, when Company’s Chief Legal Officer, Corp. Sec bought 20,000 for $0.58, making the entire transaction worth $11,520. This insider now owns 29,000 shares in total.
Context Therapeutics Inc (CNTX) Recent Fiscal highlights
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported 0 earnings per share (EPS) for the period topping the consensus outlook (set at -0.09) by 0.09. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.11 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 24.18% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 4.68% during the next five years compared to 4.72% growth over the previous five years of trading.
Context Therapeutics Inc (NASDAQ: CNTX) Trading Performance Indicators
Context Therapeutics Inc (CNTX) is currently performing well based on its current performance indicators. A quick ratio of 13.07 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.28, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach -0.41 in one year’s time.
Technical Analysis of Context Therapeutics Inc (CNTX)
Compared to the last year’s volume of 0.26 million, its volume of 0.8 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 47.63%.
During the past 100 days, Context Therapeutics Inc’s (CNTX) raw stochastic average was set at 51.99%, which indicates a significant decrease from 72.99% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0773 in the past 14 days, which was lower than the 0.0829 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1698, while its 200-day Moving Average is $0.8705. Nevertheless, the first resistance level for the watch stands at $1.1800 in the near term. At $1.2300, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.3000. If the price goes on to break the first support level at $1.0600, it is likely to go to the next support level at $0.9900. Now, if the price goes above the second support level, the third support stands at $0.9400.
Context Therapeutics Inc (NASDAQ: CNTX) Key Stats
Market capitalization of the company is 103.82 million based on 91,879K outstanding shares. Right now, sales total 0 K and income totals -26,730 K. The company made 0 K in profit during its latest quarter, and -9,690 K in sales during its previous quarter.
